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Antiphospholipid syndrome (APS) is an uncommon prothrombotic disorder that has been
increasingly recognized in recent years. The diagnosis of APS must be associated with venous
or arterial thrombosis or both. Patients with APS usually present with recurrent deep vein
thrombosis, pulmonary thromboembolism, thromboembolic stroke, or myocardial infarction.
Here, we report a case of a 61-year-old female who presented with a 3-month history of
increasingly frequent retrosternal chest tightness. After treadmill test and thallium-201
myocardial perfusion scan, she was admitted and underwent elective coronary angiography
but developed acute thrombosis after direct intracoronary stenting. She was successfully
rescued with repeat percutaneous transluminal coronary angioplasty and prolonged heparin
and glycoprotein IIb/IIIa antagonist use. Laboratory data showed prolongation of partial
thromboplastin time and positive anti-cardiolipin antibody. These findings satisfied the
criteria for APS; the patient was diagnosed with primary APS because she had neither typical
symptoms nor signs of systemic lupus erythematosus or other immunologic disorders.
Thereafter, long-term oral anticoagulant appeared to be effective. To our knowledge, this
is the first report of acute stent thrombosis in a patient with primary APS.
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Antiphospholipid syndrome (APS) is a disorder char-
acterized by venous or arterial thromboses in differ-
ent vascular territories and recurrent fetal loss, and
accompanied by increased levels of antiphospholipid
antibodies [1–3]. The syndrome may be primary or
secondary to systemic lupus erythematosus (SLE) [4].
APS has been reported as a potential risk factor for
ear ly  compl ica t ion  fo l lowing percutaneous
transluminal coronary angioplasty (PTCA) [5], and for
early bypass graft failure [6,7]. In contrast, successful
PTCA [8] and intracoronary stenting [9,10] have been
reported in cases with APS. Whether anticoagulation
and intracoronary stenting can entirely prevent acute
complication after percutaneous coronary interven-
tion (PCI) in patients with APS is still unknown. We
report here a patient with APS who presented with
angina and was managed with elective PCI by direct
intracoronary stenting over the proximal portion of
the left anterior descending (LAD) coronary artery.
An acute intra-stent thrombosis developed 30 minutes
after PCI and she was treated successfully with repeat
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PTCA and additional glycoprotein (GP) IIb/IIIa an-
tagonist use.
CASE PRESENTATION
A 61-year-old female patient presented with a 3-month
history of increasingly frequent retrosternal chest
tightness. She was a nonsmoker and had no other
major risk factors for coronary artery disease. Elec-
trocardiogram (ECG) showed a flattened T-wave over
leads III, aVF, and V2–V4. Treadmill test, arranged
due to chest tightness refractory to medical treatment,
revealed a 1–2 mm ST-segment horizontal depression
over leads V4 and V5 during exercise stage 3 at a heart
rate of 166/minute. Due to the positive treadmill test,
aspirin was prescribed. Thallium-201 myocardial
perfusion scan showed apical myocardial ischemia.
The patient was admitted for coronary angiography
(CAG). Laboratory data before CAG showed normal
plasma thromboplastin (international normalized
ratio, INR, 0.87), normal platelet count (232,000/μl),
but abnormal prolongation of partial thromboplastin
time (PTT) (65.5/32.5 sec). Heparin (5,000 units)
was administered before CAG because the activated
clotting time (ACT) was only 162 seconds. CAG re-
vealed 75% stenosis over the LAD proximal portion of
the coronary artery (Figure 1A). Under an additional
4,000 units heparin and adequate ACT (292 seconds),
direct intracoronary stenting with a Scimed Express
stent (Boston Scientific Corporation, Galway, Ireland)
was successfully performed and the acute result was
optimal (Figure 1B). Unfortunately, 30 minutes after
PCI, the patient complained of chest pain and cold
sweats refractory to nitrate and morphine. A 12-lead
ECG showed ST-segment elevation at V1–V6 and ST-
segment depression at II, III, and aVF (Figure 2). The
patient was immediately sent to the catheterization
room for emergency PTCA under the impression of
acute occlusion of the PCI. Repeat CAG revealed total
occlusion over the stent site (Figure 3A). Multiple
filling defects with thrombus formation were noted
after a guide wire was passed through the target lesion
(Figure 3B), and GP IIb/IIIa antagonist was given.
Emergency balloon angioplasty was performed and
the result was satisfactory (Figure 3C). The patient
was then given heparin and GP IIb/IIIa antagonist.
Due to the abnormal prolongation of PTT, we consid-
ered the possibility of APS and revealed the presence
of anti-cardiolipin antibody (25.6 GPL/ml) and anti-
β2 glycoprotein I antibody, but the absence of lupus
anticoagulant antibody. According to clinical presen-
tation and laboratory data, APS was suspected. The
patient was treated with low molecular weight heparin
followed by an oral anticoagulant (warfarin). She did
not complain of further chest pain and she received
regular outpatient follow-up after discharge.
Antiphospholipid antibody tests 6 weeks later re-
mained positive, with an anti-cardiolipin antibody
titer of 153.1 GPL/ml. These findings satisfied the
criteria for APS [11], and she was diagnosed with
primary APS because she had neither typical symp-
toms nor signs of SLE or other immunologic disorders.
Figure 1. Coronary angiogram (13° right anterior oblique with
35° cranial angulation) shows: (A) proximal left anterior
descending artery with 75% narrowing (arrow); and (B) no
residual stenosis in the proximal left anterior descending artery
(arrow) after direct stenting.
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Figure 3. Coronary angiogram (13° right anterior oblique with
35° cranial angulation) shows: (A) acute thrombosis (total
occlusion) over the stent-implanted area (arrow); (B) multiple
filling defects with thrombus formation over the target lesion
(arrow) after the guide wire was passed through; and (C) optimal
results (arrow) after emergency balloon angioplasty.
Figure 2. Electrocardiogram 30 minutes after percutaneous
coronary intervention, performed for chest pain, shows ST-
segment elevation at V1–V6 and ST-segment depression at II, III,
and aVF.
DISCUSSION
The spectrum of thrombotic disorders in APS spans
deep vein thrombosis, pulmonary thromboembolism,
stroke, miscarriage, and coronary events [8,12–17].
Possible mechanisms of thrombosis in patients with
APS include abnormal platelet aggregation, dysfunc-
tion of endothelial cells, and inappropriate function of
clotting components such as prothrombin, protein C,
antithrombin III, and protein S [3,18].
There have been case reports of acute myocardial
infarction in APS patients that have been treated with
thrombolytic therapy or with PCI. The Table shows
reports of APS cases managed with PCI [12,13]. Of
these six cases, early PCI failure occurred in three.
APS is a potential risk factor for early complication
following PTCA. PTCA with stenting was performed
in three cases, of which two were successful and one
was not. In the successful cases, intracoronary stenting
appeared to be a satisfactory treatment. However, in
Case 6,  stent restenosis was noted on repeat
angiography due to recurrent angina. Therefore, early
stent restenosis was still the major complication in
APS patients undergoing PCI. In our patient, elective
direct intracoronary stenting was performed but acute
thrombosis occurred. To our knowledge, this is the
first report of acute stent thrombosis in a patient with
primary APS.
In our case, clinical symptoms and signs suggest-
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ing APS were not noted before CAG, except prolonga-
tion of PTT. The prolongation of PTT in patients with
APS may cause underuse of heparin during CAG.
Therefore, complete survey of the etiology of PTT
prolongation is important before CAG. After exclud-
ing drug use and coagulation factor deficiency, inhib-
iting factors such as antiphospholipid antibody are
the most likely cause of prolonged PTT. Paradoxically,
heparin dose must be elevated in this situation be-
cause thrombosis, not bleeding, is the main presenta-
tion of this syndrome. In addition, although heparin is
not recommended after uncomplicated PCI, prolonged
heparin treatment may be beneficial in patients with
APS. Before discontinuing heparin treatment, over-
lapping use of warfarin (to maintain INR at 2.0–3.0)
should be considered.
In conclusion, PTCA with or without stenting and
long-term oral anticoagulant therapy are the most
effective treatments for coronary artery events in
patients with APS. However, in our experience, acute
thrombosis may occur in these patients in spite of
heparin and stent use. The addition of a GP IIb/IIIa
antagonist and prolonged heparin treatment are
strongly suggested in APS patients undergoing PCI.
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